Please login to the form below

ASCO 2015: What you missed in Chicago

Blue Latitude sent two of our consultants to Chicago to attend ASCO 2015, a key annual meeting for oncology specialists that brings over 30,000 delegates together to talk about innovations and progress in the field. David takes us through the highlights of the event and his take on the exciting developments that came out of the conference.

Last week, Blue Latitude sent two of our consultants to Chicago to attend ASCO 15, a key annual meeting for oncology specialists that brings over 30,000 delegates together to talk about innovations and progress in the field. David takes us through the highlights of the event and his take on the exciting developments that came out of the conference.

Medical Developments: The Immuno-oncology Era

Without question, this year really was the heralding of the immuno-oncology era, both in terms of medical developments and the great coverage ASCO got in the media. We’ve been working in immuno-oncology for a year and a half now, but we were still very impressed by the data coming out of the conference. Specifically, we thought the checkpoint inhibitors in head and neck, lung cancer and melanoma really shone. In particular, the fact that not only are the therapies showing deep responses, they are also providing a much longer duration of response, which was discussed as being a hallmark of immunological agents in oncology.  

Bristol-Myers-Squibb redefines Melanoma treatment standards

In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. However, the advantage BMS had over Roche and Merck in the programmed cell death pathway space (PD-1/PD-L1) was thrown open over a biomarker debate around activity in PD-L1 positive patients.[1] The challenge here is: firstly, there is no clear criteria for defining PD-L1 positivity (the part of the checkpoint pathway expressed on the tumour cell); and secondly, there is no standard assay to measure PD-L1 expression. I think the strength of the Checkmate-057 data[2] will ultimately give Opdivo an advantage in all patients, but I also think that how the other PD-1/PD-L1s challenge Opdivo will depend on how the European markets provide access to it, as well as how issues of cost versus value of the treatment are addressed.  

Personalised treatments: targeting genetic mutations to treat cancer

The second area that really impressed me was the large National Cancer Institute (NCI) trial[3] that will look to treat patients with solid tumours based on their genetic mutations and not their organ of origin. A list of targeted treatments, such as crizotinib and TDM-1, will be used to target specific genetic abnormalities in patients’ tumours. This represents a real step forward in terms of precision medicine, which will further link whole genomic screening to the tailoring of an individual patient’s treatment. It will be extremely exciting to see what comes out of this trial.    

Transforming multiple myeloma treatment with monoclonal antibodies

The third area was the arrival of breakthrough therapies in plasma cell disorders. Three monoclonal antibodies were presented on the last day of ASCO - two in multiple myeloma and one in amyloidosis. For years, leukaemia and lymphoma patients have benefited from power of monoclonal antibody treatment while plasma cell malignancies showed little activity with CD20 targeting treatment. In multiple myeloma, we saw data from two immunotherapies showing clinical activity. In particular, daratumumab in double refractory multiple myeloma represents a truly transformational treatment in this area for patients who have tried all current options[4]. In an area dominated by combination trials, daratumumab showed significant single agent activity in this hard to treat population with tolerable safety profile.  

ASCO 15: Highlighting innovation and raising key questions

Amgen and AstraZeneca had excellent booths that were extremely interactive with some great educational tools. The Amgen booth had a giant mechanical puppet show that explained their BITE technology, while AstraZeneca used the Oculus Rift to describe the how and why around various cellular pathways they were developing treatments for to great effect.   Overall, ASCO15 was a great place to be this year with all the exciting innovations in cancer treatments that were announced. However, oncology specialists and healthcare practitioners more generally will have their work cut out for them in taking this information on board and incorporating these new treatment options into their practise. Questions around cost and value still need to be urgently addressed by the medical community if the goal is to deliver personalised cancer treatment to patients across the world.    

These are the topics we discuss at Blue Latitude, both internally and externally, with our clients and a range of stakeholders whom we carry out primary research with. If you would like to discuss ASCO15 or immuno-oncology with us further, please reach out to Matt, our Head of Commercial at:

[1] PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Patel SP et al Mol Cancer Ther 2015 [2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. Larkin et al 2015 NEJM [3] NCI Prepares to Launch MATCH Trial. Cancer Discov. 2015 [4] NCT01985126 An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma… 2015

15th June 2015



Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Blue Latitude Health
Crusader House
145-157 St John Street
United Kingdom

Latest content on this profile

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big data.
Blue Latitude Health
Lynch syndrome: a patient perspective
Blue Latitude Health intern Costantino Ciotti gives an insight into life with Lynch Syndrome, a genetic condition associated with colon cancer. Here he explores the patient’s perspective, including treatment options, and gives his advice for healthcare professionals diagnosing patients with a genetic disease.
Blue Latitude Health
What does programmatic advertising mean for your pharma marketing strategy?
Senior Associate Consultant Jiayi Chen explains the benefits and pitfalls of programmatic advertising and reveals how it can impact return on investment in your marketing campaigns.
Blue Latitude Health
How to measure marketing success: profit vs ROI
Measuring marketing activity is proving to be a major challenge in pharma. Here, Senior Consultant Paul Townley-Jones explores the meaning of success and gives his tips for measuring efficiency and effectiveness, along with the formula for calculating profit and ROI.
Blue Latitude Health
Perspective on biotech leaders
In the latest issue of Perspective magazine, seven industry trailblazers reveal the trends, challenges and opportunities they anticipate in the biotech sector, from empowering patients to deciphering big data.
Blue Latitude Health
Global customer research in healthcare: 10 tips for capturing insights that matter
What makes a strong brand? One global core coupled with sensitivity to regions and countries. In part two of our series on customer insight and behaviour change, we share our tips on optimising global customer research projects to ensure you get the balance right in an efficient way.
Blue Latitude Health